NextCure (NXTC) Projected to Post Earnings on Monday

NextCure (NASDAQ:NXTC) is anticipated to announce its Q2 2026 results before the market opens on Monday, August 3rd. Analysts expect NextCure to post earnings of ($1.95) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:00 PM ET.

NextCure (NASDAQ:NXTC) last posted its earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.10) by $0.23. On average, analysts expect NextCure to post $-8 EPS for the current fiscal year and $-8 EPS for the next fiscal year.

NextCure Stock Performance

Shares of NXTC stock opened at $4.14 on Friday. NextCure has a 52 week low of $1.55 and a 52 week high of $15.74. The company’s 50 day moving average price is $3.49 and its two-hundred day moving average price is $8.68. The company has a market capitalization of $14.95 million, a P/E ratio of -0.24 and a beta of 1.42.

Insiders Place Their Bets

In other news, major shareholder Adar1 Capital Management, Llc purchased 7,798 shares of NextCure stock in a transaction on Monday, July 27th. The stock was purchased at an average price of $5.00 per share, with a total value of $38,990.00. Following the transaction, the insider directly owned 383,456 shares in the company, valued at $1,917,280. The trade was a 2.08% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last three months, insiders purchased 17,608 shares of company stock worth $87,720. Corporate insiders own 11.90% of the company’s stock.

Institutional Trading of NextCure

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Ikarian Capital LLC acquired a new position in NextCure during the fourth quarter worth $3,382,000. Squadron Capital Management LLC bought a new position in NextCure in the fourth quarter valued at $3,363,000. Millennium Management LLC acquired a new stake in NextCure in the 4th quarter valued at $185,000. Boothbay Fund Management LLC acquired a new stake in NextCure in the 4th quarter valued at $988,000. Finally, Marshall Wace LLP bought a new stake in NextCure during the 4th quarter worth about $160,000. 42.65% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NXTC has been the subject of several research reports. Weiss Ratings downgraded shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 7th. Zacks Research raised shares of NextCure from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 11th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of NextCure in a report on Wednesday, July 15th. Finally, Wall Street Zen cut NextCure from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $19.00.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.